CytoDyn Completes Safety Testing of Cytolin[R]: Benchmark for Improved Treatment of HIV/AIDS.
Linked as:
Extract
CytoDyn Completes Safety Testing of Cytolin[R]: Benchmark for Improved Treatment of HIV/AIDS.
SANTA FE, N.M. -- CytoDyn, Inc. (Pink Sheets:CYDY) has completed safety testing of its current inventory of Cytolin([R]), the Company's immune-system modulator for managing HIV disease and the public health crisis afflicti...
See the full content of this document
Sponsored links
